Table 2. Sensitivity, specificity, PPV and NPV of the FPG and HBA1C tests in the diagnosis of diabetes and AGR at the OGTT cut-offs recommended by ADA and WHO.
| Test | Sensitivity, % | Specificity, % | PPV | NPV | |||||
|---|---|---|---|---|---|---|---|---|---|
| (95% CI) | (95% CI) | ||||||||
| Diabetes | FPG | 62.6 (41.5–79.8) | 99.4 (98.9–99.7) | 0.91 | 0.97 | ||||
| HBA 1C | 69.8 (46.3, 86.1) | 98.6 (95.4–99.6) | 0.82 | 0.97 | |||||
| AGR | Based on ADA criteria | Based on WHO criteria | Based on ADA criteria | Based on WHO criteria | Based on ADA criteria | Based on WHO criteria | Based on ADA criteria | Based on WHO criteria | |
| FPG | 47.7 (37.3–58.4) | 29.0 (22.5–36.6) | 93.5 (88.6–96.4) | 98.3 (97.4–98.9) | 0.74 | 0.87 | 0.82 | 0.78 | |
| HBA 1C | 58.9 (46.7–70.2) | NA | 70.7 (65.1–75.8) | NA | 0.45 | NA | 0.82 | NA | |